Cish Inactivated Tumor Infiltrating Lymphocytes
Lung Adenocarcinoma
Explore 64 assets in Lung Adenocarcinoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Intima Bioscience, Inc.
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05566223CT.gov CISH Inactivated TILs in the Treatment of NSCLC | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cish Inactivated Tumor Infiltrating Lymphocytes (this asset) | Intima Bioscience, Inc. | P1/2 | CCC · 48 |
| Carboplatin | Guangdong Association of Clinical Trials | P3 | BBB |
| Cyclophosphamide | Anusha Kalbasi | P2 | BBB |
| Etoposide | Guangdong Association of Clinical Trials | P3 | BB |
| Nivolumab | Emory University | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Guangdong Association of Clinical Trials | P3 | BB |
| Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Osimertinib | Shanghai Chest Hospital | P2 | BB |
| Vinorelbine Ditartrate | AIO-Studien-gGmbH | P3 | BB |
+42 more in the Lung Adenocarcinoma cohort
Other indications for Cish Inactivated Tumor Infiltrating Lymphocytes
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P1/2 | CCC · 48 |
| Squamous Cell Lung Carcinoma | — | P1/2 | CC · 47 |
| Non-Small Cell Lung Carcinoma | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cish Inactivated Tumor Infiltrating Lymphocytes in Lung Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cish-inactivated-tumor-infiltrating-lymphocytes-lung-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →